Entero Therapeutics Inc (ENTO) USD0.0001

Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The Company is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The Company is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.